Holen Sie sich die Stockscreener-App
803.17
2.49%
19.52
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
LSV Asset Management Takes $31.26 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Cibc World Market Inc. Has $8.85 Million Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Allergy Data And Dupixent Insights Shape Immunology Growth Story - simplywall.st
CRISPR Therapeutics Spotlights Momentum For Lead Gene Therapy As Adoption Widens - Benzinga
Where is Regeneron Pharmaceuticals (REGN) Headed According to Analysts? - Insider Monkey
HSBC Adjusts Price Target on Regeneron Pharmaceuticals to $990 From $985, Maintains Buy Rating - marketscreener.com
Krilogy Financial LLC Invests $1.18 Million in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Illinois Municipal Retirement Fund Buys 2,599 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron, Samsung Bioepis Settle Eylea Biosimilar Patent Case - Bloomberg Law News
Regeneron, Samsung Bioepis Settle Eye Med Patent Claims - Law360
Sanofi and Regeneron Advance Itepekimab Bet With Completed Phase 2 Bronchiectasis Trial - TipRanks
Will Eylea Sales Decline Weigh on REGN's Top Line in 2026? - TradingView
Rhumbline Advisers Cuts Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Leuthold Group LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
115,028 Shares in Regeneron Pharmaceuticals, Inc. $REGN Bought by Sound Shore Management Inc CT - MarketBeat
Prospera Financial Services Inc Has $4.93 Million Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Block Graft Market Is Going to Boom | Regeneron Pharmaceuticals • Novartis • Pfizer - openPR.com
1 Healthcare Stock Worth Your Attention and 2 Facing Challenges - Finviz
Samsung Bioepis to launch ophthalmology biosimilar in U.S. next year - Yonhap News Agency
Regeneron Pharmaceuticals (NASDAQ:REGN) Director Sells $77,853.00 in Stock - MarketBeat
Insider Selling: Arthur Ryan Sells Shares of Regeneron Pharmaceu - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) SVP Sells $1,585,066.72 in Stock - MarketBeat
How to watch Regeneron's March healthcare investor talks - Stock Titan
Regeneron Announces Investor Conference Presentations - The Manila Times
Regeneron Pharmaceuticals Officer Sells Over $1.5 Million in Company Stock - TradingView
A Look At Regeneron (REGN) Valuation As Recent Share Weakness Meets An 8.1% Undervaluation Estimate - simplywall.st
Trading Systems Reacting to (REGN) Volatility - Stock Traders Daily
Skylands Capital LLC Acquires New Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ING Groep NV Grows Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Baader Bank Aktiengesellschaft - MarketBeat
The Zacks Analyst Blog Highlights NVIDIA, Amazon.com, Regeneron, National Presto and AXIL - Yahoo Finance
Regeneron to present Phase 3 data on novel allergy antibodies at AAAAI - Investing.com South Africa
Evommune’s Atopic Dermatitis Data Competitive With Dupixent - Citeline News & Insights
Top Stock Reports for NVIDIA, Amazon & Regeneron - Nasdaq
Regeneron Pipeline Progress Continues but Near-Term Visibility Remains Limited, RBC Says - marketscreener.com
Sanofi (SNY) Collaborates on New Allergy Treatment Insights - GuruFocus
United States Biotechnology Market to hit US$ 1.5 Trillion - openPR.com
Regeneron Highlights Expanding Immunology Portfolio and Pipeline at AAAAI, Showcasing Novel Approaches to Treating Allergy - The Manila Times
Regeneron Pharmaceuticals showcases 36 breakthroughs at AAAAI26 - Traders Union
Regeneron Rose 3% This Week. Here’s Where the Stock Could Be Headed in 2026 - TIKR.com
New antibody cocktails for cat and birch allergies show first Phase 3 data - Stock Titan
Should Regeneron’s (REGN) EYLEA HD Milestones and Buybacks Reshape Its Long-Term Investment Narrative? - simplywall.st
Envestnet Asset Management Inc. Cuts Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
ProShare Advisors LLC Trims Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Oppenheimer & Co. Inc. Increases Stake in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Guggenheim Raises Price Target for Regeneron Pharmaceuticals (RE - GuruFocus
Regeneron Pharmaceuticals (NASDAQ:REGN) Given New $975.00 Price Target at Guggenheim - MarketBeat
Guggenheim raises Regeneron stock price target to $975 on Dupixent growth - Investing.com
Candriam S.C.A. Has $95.30 Million Stock Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Bessemer Group Inc. Raises Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Savant Capital LLC Boosts Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Sanofi (SNY) Strengthens Shareholder Returns Amid Robust 2025 Performance and Long-Term Growth Outlook - Finviz
Thrivent Financial for Lutherans Sells 1,978 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Wall Street Zen Upgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Purchased by Murphy Pohlad Asset Management LLC - MarketBeat
Prime Capital Investment Advisors LLC Buys 11,835 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Data On EYLEA HD Dosing Shapes Retinal Disease Outlook - simplywall.st
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Recent Share Price Pullback - Yahoo Finance
Regeneron (REGN) Q2 2025 Earnings Call Transcript - AOL.com
Regeneron holiday party tops Albany Capital Center revenue list - The Business Journals
Bronte Capital Management Pty Ltd. Trims Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
The Top 12 Companies Hiring in Biopharma Now - BioSpace
Regeneron’s Expanding AI Use Raises Data Privacy, Regulatory and Market Risks - TipRanks
Decoding Regeneron Pharmaceuticals Inc (REGN): A Strategic SWOT Insight - GuruFocus
Regeneron Pharmaceuticals, Inc. (REGN): A Bull Case Theory - Finviz
1.39%
5.69%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):